ARTICLE | Company News

Emergent BioSolutions, Temasek Life Sciences Laboratory deal

August 16, 2010 7:00 AM UTC

Emergent and Temasek Life Science Ventures Pte. Ltd. will form Epic Bio Pte. Ltd., a JV to develop and commercialize a pandemic vaccine against H5N1 influenza strains. Temasek Life Science Ventures is an investment holding vehicle for Temasek Life Sciences Laboratory (TLL). The multivalent, cross-protective vaccine will use multiple antigens from Temasek and be delivered as a single vaccine using Emergent's MVAtor vaccine delivery technology. Phase I testing is expected to begin in 2012. The JV also will develop mAbs to treat pandemic H5N1 influenza using Temasek's monoclonal technology. ...